Expiry of key patents
|
|
|
Key patents or data exclusivity expires
|
| Molecule |
Product |
Indication |
Europe |
USA |
Japan |
| Entacapone |
Stalevo®, Comtess®, Comtan® |
Parkinson's disease |
Nov 2012
Oct 2013 3) |
Oct 2013 1) |
Jan 2015 2) |
| Levosimendan |
Simdax® |
acute decompensated heart failure |
Sep 2015 |
not approved |
not approved |
| Dexmedetomidine |
Precedex®,
Dexdomitor®,
dexdor® |
sedative for humans and animals |
Jul 2013 4)
Mar 2019 5) |
Jul 2013 |
Jun 2012 |
1) Market entry by Wockhardt and Sun companies asagreed as of April 2012
2) Date exclusivity ends; currently only Comtan available, Stalevo development project for Japanese market on-going
3) Stalevo data protection ends
4) In Europe 10 year data exclusivity possible after centralised marketing approval.(Dexdomitor)
5) Use of dexmedetomidine for ICU sedation
Updated
Feb 22nd 2012